Liraglutide Research
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass
Diabetes Research and Clinical Practice·March 1, 2026
Valeria Gutierrez de Piñeres, Arantxa Ramirez-Cisneros, Claudia S. Tamayo-Torres, Angeliki M. Angelidi, Marianthi Kavelidou, Konstantinos Stefanakis, Christos S. Mantzoros
Summary
Liraglutide reduced body weight, BMI, and total/regional mass. Absolute fat-free mass slightly but significantly lower. Relative lean mass percentages remained stable.
Study Details
Study Design
Randomized placebo-controlled crossover trial
Indication
Obesity
Intervention
Liraglutide 3.0 mg/day vs placebo for 35 days
Species
Human
Sample Size
20 subjects